Safety of a probiotic cheese containing Lactobacillus plantarum Tensia according to a variety of health indices in different age groups  by Songisepp, E. et al.
5495
J. Dairy Sci.  95 :5495–5509
http://dx.doi.org/ 10.3168/jds.2011-4756 
© American Dairy Science Association®,  2012 .
 ABSTRACT 
 Safety of the probiotic Lactobacillus plantarum strain 
Tensia (DSM 21380) was tested in vitro, in semihard 
Edam-type cheese, in an animal model and after 
consumption of the probiotic cheese in double-blind 
randomized placebo-controlled human intervention 
studies with different age groups. The susceptibility of 
L. plantarum Tensia to 8 antibiotics, and the presence 
of tetracycline (tet M, S, O, K, L) genes and class 1 
integron was assessed by applying epsilometer-test and 
PCR-based methods. Production of biogenic amines 
by the probiotic strain in decarboxylation medium 
containing 1% of l-histidine, l-glutamine, l-ornithine, 
l-arginine, or l-lysine and in cheese was tested by gas 
chromatography. The biosafety of L. plantarum Tensia 
was evaluated on National Institutes of Health-line 
mice fed cheese containing Tensia at a concentration 
of 9.6 log cfu/g for 30 consecutive days. In human in-
tervention trials in adults and the elderly, the effects of 
different doses of Edam-type cheese and the probiotic 
bacterium on BW, gut functionality indices, and host 
metabolism were evaluated. The strain L. plantarum 
Tensia was susceptible to all tested antibiotics and 
did not possess the tetracycline resistance-determining 
genes tet(L), tet(S) and tet(O), nor did it contain the 
integron (Int1) gene. However, the strain was tet(K) 
and tet(M) positive. Lactobacillus plantarum Tensia did 
not produce potentially harmful biogenic amines, such 
as histamine or cadaverine. The amount of tyramine 
produced in the cheese environment during ripening 
and after 15 wk of storage was below the clinically 
significant content. In the animal model, no transloca-
tion of the administered strain or other microbes into 
the blood or organs of mice was detected. No harmful 
effect was observed on body mass index, inflammatory 
markers, or serum lipidograms during human interven-
tion trials with different age groups at a daily dose 
of 10.3 or 8.17 log cfu/serving for 3 wk. No negative 
effect on gastrointestinal welfare was observed, but the 
consumption of 100 g/d for 3 wk caused hard stools 
from the second week of the trial. The content of total 
lactobacilli increased in feces, and the presence of the 
ingested probiotic strain was confirmed after the con-
sumption of cheese. Thus, L. plantarum strain Tensia 
is suitable for generally recognized as safe (GRAS) and 
qualified presumption of safety (QPS) criteria because 
it did not have any undesirable characteristics. The 
regular semihard Edam-type cheese (fat content of 
26%) with the probiotic additive at a daily dose of 50 g 
or in excess (100 g) and with a probiotic daily dose of 
10 log cfu for 3 wk was safe. 
 Key words:   Edam-type cheese ,  Lactobacillus planta-
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 INTRODUCTION 
 To date, the close link between intestinal microbiota, 
nutrition, and human metabolism has increased interest 
in functional food applications (e.g., pre- and probiotic 
products) for health promotion in different age groups. 
A variety of probiotic dairy products, including cheeses 
with particular functional properties, is available on the 
market worldwide (Gomes et al., 1995; Gardiner et al., 
1998; Songisepp et al., 2004; Ross et al., 2005; Ibrahim 
et al., 2010). Probiotics are defined as live microorgan-
isms, which, when consumed in appropriate amounts 
in the food, confer a health benefit on the host (FAO/
WHO, 2002). Their identity, safety, and health claims 
have attracted a large amount of attention from differ-
ent public and regulatory organizations. 
 The putative probiotic strain should be accurately 
characterized and identified (Vankerckhoven et al., 
2008), with its functional properties and the ability 
for temporal colonization (bile, gastric acid tolerance, 
and adhesive properties) confirmed in vitro (Saarela et 
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al., 2000; Kõll et al., 2010). Recent recommendations 
include the absence of hemolytic activity and transfer-
able antibiotic resistance of the selected Lactobacillus 
strain, whereas the safety should be proven in animal 
models (FAO/WHO, 2002; Vesterlund et al., 2007; Kõll 
et al., 2010). Next, pilot clinical trials on healthy vol-
unteers are needed, to exclude probiotic administration 
having adverse effects on gut health and biochemical 
and cellular indices of the blood, reflecting the proper 
functions of human organs (Reid, 2005; Mercenier et 
al., 2008; Rijkers et al., 2010). Further, only after these 
procedures should the expression of the functional 
properties of the strain—either by improving some 
physiological functions (e.g., antimicrobial, metabolic, 
immunogenic, antioxidative) of the host or by reduc-
ing the risk of some diseases after consumption of the 
probiotic product—be tested in large groups of volun-
teers. Several studies have found an inverse relationship 
between the intake of low-fat dairy products and the 
incidence of cardiovascular diseases (CVD), preclini-
cal atherosclerosis, and cardiovascular risk factors in 
middle-age and older age persons (Djoussé et al., 2006; 
Engberink et al., 2009; Levitan et al., 2009; Toledo et 
al., 2009). However, few safety assessments have been 
directed toward the control of biomarkers of host basic 
metabolism, particularly carbohydrates, lipids, and AA 
turnover, after administration of a dairy probiotic. Fur-
thermore, it has not been elucidated how the addition 
of a probiotic strain to a full-fat dairy product affects 
gut functionality indices of the host.
Here, we report on clinical probiotic food interven-
tion trials in adults and the elderly in which the toler-
ability and safety of a cheese containing a probiotic 
Lactobacillus plantarum strain was tested according to 
multiple health markers. In particular, a regular Edam-
type cheese containing the probiotic L. plantarum 
strain Tensia (DSM 21380) was clinically evaluated in 
healthy Estonian individuals of 2 different age groups 
(adults and the elderly). The effects of different doses 
of cheese and probiotic bacteria on gut health indices; 
BW; functionality markers of the liver and kidneys; and 
hematological (hemoglobin, erythrocytes, and lympho-
cytes), metabolic (plasma glucose, glycohemoglobin, 
and lipids), and inflammatory indices [white blood cell 
count, high-sensitivity C-reactive protein (hs-CRP)] 
were evaluated.
MATERIALS AND METHODS
Probiotic Strain
A novel probiotic Lactobacillus strain was previ-
ously isolated from a fecal sample of a healthy child 
(Mikelsaar et al., 2002; Annuk et al., 2003). The mo-
lecular identification of the strain as L. plantarum was 
confirmed by internal-transcribed spacer PCR and 
16S rRNA sequencing. The functional properties and 
health effects of the strain have been described else-
where (Songisepp et al., 2009). The strain L. plantarum 
Tensia was deposited in Deutsche Sammlung von Mik-
roorganismen und Zellkulturen GmbH (Braunschweig, 
Germany) under the registration number DSM 21380 
on April 16, 2008.
Hemolytic Activity
A single line of lactobacilli culture [grown in de Man, 
Rogosa, Sharpe broth (MRS; Oxoid, Basingstoke, UK) 
for 48 h] was streaked onto blood agar plates containing 
either human or sheep blood. Hemolysis of L. plantarum 
Tensia was evaluated after 24 and 48 h of incubation in 
aerobic, microaerobic (10% CO2), and anaerobic (90% 
N2, 5% CO2, 5% H ) environments. One Staphylococ-
cus aureus strain (ATCC 25923) and 1 Streptococcus 
pyogenes strain (ATCC 19615) were used as positive 
controls.
Antibacterial Susceptibility Testing
The susceptibility to kanamycin, ampicillin, genta-
micin, streptomycin, erythromycin, clindamycin, tetra-
cycline, chloramphenicol, and quinupristin/dalfopristin 
was assessed according to European Union Commission 
recommendations for probiotic safety (EFSA, 2008). 
The MIC of antibiotics to L. plantarum Tensia was 
determined by applying an epsilometer-test strip (AB 
Biodisk, Piscataway, NJ; Mayrhofer et al., 2008) on an 
inoculated Lactic Acid Bacteria Susceptibility Test Me-
dium containing Iso-Sensitest agar (90%, vol/vol) and 
MRS agar (10%, vol/vol), pH 6.7 (both from Oxoid; 
Klare et al., 2005). The results were read after 24 h 
of incubation at 35°C in a microaerobic environment 
(CampyPak Plus, BD, Franklin Lakes, NJ).
Presence of tet and Int1 Genes Analyzed by PCR
Total DNA of L. plantarum Tensia was extracted us-
ing a QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, 
Germany) following the manufacturer’s protocol. Poly-
merase chain reactions were carried out in a 50-μL 
volume containing 10× PCR buffer, 2.5 mM MgCl2, 2.5 
mM deoxynucleotide 5c-triphosphates, 20 pmol of each 
primer (Table 1), 2.5 U of Taq polymerase (Fermentas, 
Vilnius, Lithuania), and 2 μg of template DNA. For de-
tection of the possible presence of tet genes encoding ri-
bosomal protection proteins, the degenerate primers DI 
and DII were used. If positive, additional PCR assays 
were performed with primers specific for the tet(M), 
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tet(O), and tet(S) genes. Next, L. plantarum Tensia was 
tested for the presence of the tetracycline efflux genes 
tet(K) and tet(L) (Gevers et al., 2003a,b).
For detection of the possible presence of integron, a 
class 1 integrase-specific fragment of the Int1 gene was 
used (Lévesque et al., 1995). Polymerase chain reaction 
amplicons for tet genes were performed in an Eppendorf 
PCR System (Eppendorf AG, Hamburg, Germany) 
with the following programs: initial denaturation at 
94°C for 5 min; 35 cycles of 94°C for 1 min, anneal-
ing temperature [ribosomal protection protein gene at 
45°C; tet(M), tet(K), tet(L), tet(S), and tet(O) at 55°C] 
for 1 min, and 72°C for 2 min; and a final extension 
step at 72°C for 10 min. Amplification specifications 
for integrase Int1 were as follows: 94°C for 5 min, fol-
lowed by 25 cycles of 94°C for 30 s, 55°C for 30 s, and 
72°C for 30 s, and a final extension at 72°C for 7 min. 
Amplicons were electrophoresed on 1.5% agarose gel, 
and a 1-kb ladder (Fermentas) was used as a molecular 
size marker.
Production of Biogenic Amines
In Decarboxylation Medium. Lactobacillus plan-
tarum Tensia strain DSM 21379 and Escherichia coli 
ATCC 700336 were used as positive controls. A 0.5-mL 
(9-log cfu/mL) amount of the microbial suspension was 
further seeded into 4.5 mL of the decarboxylase broth 
(Difco Decarboxylase Base Moeller, BD) containing 
1% of l-histidine, l-glutamine, l-ornithine, l-arginine, 
or l-lysine and incubated at 37°C for 4 d. A 200-μL 
volume of reaction medium was derivatized for gas 
chromatography analysis by a modification of the 
method of Nakovich (2003). For detection of biogenic 
amines (BA), gas chromatography analyses were car-
ried out using an HP 6890 Series GC System with an 
HP-5 19091J-413 capillary column (30 m × 0.32 mm; 
0.25 μm i.d.; Agilent, Santa Clara, CA). The column 
temperature program was 160°C and was held for 1 min 
and increased at 20°C/min to 280°C for 15 min; the 
flame-ionization detector temperature was 300°C.
In Milk. Fat-free milk was inoculated with 107 cfu/
mL of the Tensia strain and incubated at 37°C for 40 d. 
Samples were taken at the beginning of the trial and on 
d 12 and 40 from the inoculation.
Cheese Containing L. plantarum Tensia
Gas chromatography profiles of propyl chloroformate 
amines extracted from cheese samples were detected. 
The cheese samples were extracted as follows: 20 mL 
of 50% methanol solution was added to 10 g of cheese 
and incubated at 45°C for 1 h, cooled to 30°C, and 
centrifuged. A 200-μL volume of the upper layer was 
derivatized for gas chromatography and analyzed by a 
modification of the method of Nakovich (2003).
Cheese Preparation
The probiotic cheese containing L. plantarum Tensia 
was developed at the Dairy Cooperative E-Piim, (Põlt-
samaa, Estonia). Shortly thereafter, semihard Edam-
type cheeses were prepared from cow’s milk with 0.8 
to 1% of C92 precultured cheese starter (CSK Food 
Enrichment, Leeuwarden, the Netherlands). Two dif-
ferent cheeses were prepared: regular Edam-type cheese 
as the control, and Edam-type cheese containing the 
L. plantarum strain Tensia as an adjunct starter. The 
total counts of live L. plantarum Tensia per gram of 
cheese are presented in Table 2. Before renneting, L. 
plantarum Tensia was added to the pasteurized milk to-
gether with the starter. The milk was renneted (25 min 
Table 1. Primers for PCR detection of the tet and Int genes1 
Primer pair
Gene(s) 
targeted Sequence
DI RPP 5c-GAYACNCCNGGNCAYRTNGAYTT-3c
DII RPP 5c-GCCCARWANGGRTTNGGNGGNACYTC-3c
DI tet(M) 5c-GAYACNCCNGGNCAYRTNGAYTT-3c
TetrM-R tet(M) 5c-CACCGAGCAGGGATTTCTCCAC-3c
TetO-f tet(O) 5c-AATGAAGATTCCGACAATTT-3c
TetO-r tet(O) 5c-CTCATGCGTTGTAGTATTCCA-3c
TetS-f tet(S) 5c-ATCAAGATATTAAGGAC-3c
TetS-r tet(S) 5c-TTCTCTATGTGGTAATC-3c
TetK-f tet(K) 5c-TTATGGTGGTTGTAGCTAGAAA-3c
TetK-r tet(K) 5c- AAAGGGTTAGAAACTCTTGAAA-3c
TetL-f tet(L) 5c-GTMGTTGCGCGCTATATTCC-3c
TetL-R tet(L) 5c-GTGAAMGRWGCCCACCTAA-3c
5cCS Int1 5c-GGCATCCAAGCAGCAAG-3c
3cCS Int1 5c-AAGCAGACTTGACCTGA-3c
1DI and DII = degenerate primers; RPP = ribosomal protection protein; CS = conserved segment; tet = tet-
racycline; Int = integron.
5498 SONGISEPP ET AL.
Journal of Dairy Science Vol. 95 No. 10, 2012
at 32°C) in the presence of CaCl2 (E-509) and KNO3 
(E-252; Chy-Max, Chr. Hansen, Hørsholm, Denmark). 
The curds were cut (10 to 15 min), heated (38 to 42°C), 
dried (25 min), pressed (70 min, 37 to 41°C), drained (1 
h), salted at 12°C for 24 h (pH 4.5 to 4.9, salt concen-
tration >1,151 g/mL), drained and dried (30 min to 24 
h), and coated with plastic. The ripening of the cheese 
lasted 4 wk at 10 to 12°C at a relative air humidity of 
80 to 85%.
The nutrient value of 100 g of cheese was as follows: 
lipids, 26 g; proteins, 26.4 g; carbohydrates and fiber, 
0 g; saturated fatty acids, 16 g; vitamin A, 0.23 mg; 
vitamin B2, 0.37 mg, and vitamin C, 3 mg. The energy 
provided by consuming 100 g of the cheese was 350 kcal 
or 1,488 kJ.
In Vivo Animal Trial
The biosafety of cheese containing L. plantarum 
Tensia was evaluated in a mouse model according to 
guidelines suggested by the Federation of European 
Laboratory Animal Science Association (Nicklas et 
al., 2002). The animal trial protocol was approved by 
the Ethics Committee on Animal Experiments of the 
Ministry of Agriculture of Estonia (protocol number 
67/09.11.06).
Altogether, 20 National Institutes of Health mice 
(Harlan Laboratories Inc., Blackthorn, UK) were in-
volved. Throughout the study, the mice were given a 
commercial diet (R-70; Lactamin, Kimstad, Sweden) 
and tap water ad libitum and a 50-g amount of cheese 
was added per cage daily. The average consumption 
of cheese per mouse per day was calculated after the 
leftover cheese was weighed. Ten mice belonged to the 
test group fed the probiotic cheese containing L. plan-
tarum Tensia at a concentration of 9.6 log10 cfu/g for 
30 consecutive days. A control group was fed the same 
amount of regular cheese without added lactobacilli.
Changes in behavior, coat texture, physical activity, 
and general health of the animals as well as changes in 
BW and related changes in food and water consump-
tion were observed daily according to the Organisation 
for Economic Co-operation and Development Guidance 
Document (OECD, 2000). Feces for counts of lacto-
bacilli were sampled on d 0, 3, 10, 15, 20, and 30. For 
histological analysis, tissue sections of the liver, spleen, 
kidneys, and lungs of killed mice were fixed in 10% of 
formaldehyde and embedded in paraffin. The samples 
were stained with hematoxylin and eosin and by using 
the van Gieson method. Alterative and inflammatory 
changes in tissues were evaluated.
Mice were killed by cervical dislocation on d 30, and 
samples were collected for microbiological analyses. 
Heart blood (10 μL) and homogenized tissue of the 
liver and spleen were tested for possible translocation 
of gut microbiota and L. plantarum Tensia onto blood 
and MRS agar, and for counts of lactobacilli, samples 
of the small intestine and large intestine were plated 
onto MRS agar (Oxoid). After 48 h of incubation in an 
aerobic (blood agar plates) and a microaerobic envi-
ronment (MRS plates), colonies were enumerated. The 
Lactobacillus spp. were identified according to gram 
staining, colony and cell morphology, a negative cata-
lase reaction, and carbohydrate fermentation patterns.
Design of Human Volunteer Trials
The present study was conducted according to guide-
lines laid down in the Declaration of Helsinki. All tri-
als were carried out in accordance with good clinical 
practice (GCP) and approved by the Ethics Review 
Committee on Human Research of the University of 
Table 2. Designs of intervention studies with healthy adults and the elderly 
Variable
DBPC1 intervention study Open-label intervention study
Study 1 Study 2 Study 3
Study acronym TE 1 ELD TE 5
ISRCTN2 ISRCTN38739209 ISRCTN45791894 ISRCTN42449576
Duration of the trial (wk) 8 8 3
Duration of the test period (wk) 3 3 3
Duration of washout (wk) 2 2 —
Duration of the control period (wk) 3 3 —
Probiotic count in the cheese log (cfu/g) 8.7 6 8.3
Daily dose of probiotic (log10 cfu) 10.4 8.17 10.3
Daily dose of cheese (g) 50 50 100
Cheese age (wk) 12 to 15 13 to 16 12 to 15
Fat intake with cheese (g/d) 13 13 26
Saturated fat intake with cheese (g/d) 8 8 16
Cholesterol intake with cheese (mg/d) 45 45 89
1DBPC = double-blind placebo-controlled.
2ISRCTN = International Standard Randomized Controlled Trial Number.
Journal of Dairy Science Vol. 95 No. 10, 2012
SAFETY OF A PROBIOTIC CHEESE 5499
Tartu, Estonia (protocol nos. 158/10 from March 26, 
2007; 177/T-13 from December 12, 2008; and 190/10 
from 2010). All participants provided written informed 
consent at the enrollment of the study and were given 
the possibility of withdrawing from the study at any 
time.
Three different trials were conducted. Study 1 (TE 
1), a double-blind placebo-controlled (DBPC) cross-
over study [International Standard Randomized Con-
trolled Trial Number (ISRCTN) ISRCTN38739209], 
was performed to investigate the tolerability and safety 
of semihard Edam-type cheese containing L. plantarum 
strain Tensia on healthy adults.
Within 1 mo before the beginning of the study, 
participants were asked to continue their normal diet 
except to avoid probiotic products (e.g., food supple-
ments, cheese, yogurt, kefir). The trial began with par-
ticipants consuming 50 g of the test cheese [i.e., cheese 
containing L. plantarum Tensia (verum)] daily for 3 
wk. The trial was begun with the test cheese because 
otherwise the control cheese could have influenced the 
evaluation of tolerability of the study product under 
investigation. After a 2-wk washout period, volunteers 
were crossed over to another 3 wk of consuming the 
control cheese (i.e., cheese without L. plantarum Ten-
sia; Table 2, Figure 1).
Study 2 (ELD), a second DBPC crossover trial 
(ISRCTN45791894), was performed to investigate the 
safety of semihard Edam-type cheese containing L. 
plantarum strain Tensia on health markers in healthy 
elderly participants. Within 1 mo before the beginning 
of the study, participants were asked to continue their 
normal diet except to avoid probiotic products (e.g., 
food supplements, yogurt, cheese, kefir). The trial be-
gan with 3 wk of participants consuming 50 g of the 
test cheese [i.e., cheese containing L. plantarum Tensia 
(verum)] daily. The trial was begun with the test cheese 
because otherwise the control cheese could have influ-
enced the evaluation of tolerability of the study prod-
uct under investigation. After a 2-wk washout period, 
volunteers were crossed over to another 3 wk of control 
cheese (i.e., cheese without L. plantarum Tensia) con-
sumption (Table 2, Figure 1).
Study 3 (TE 5), an open-label intervention study 3 
(ISRCTN42449576), was performed to investigate the 
safety and dose-response effects of semihard Edam-type 
cheese containing L. plantarum strain Tensia on health 
markers in healthy adults. After a 3-wk run-in period, 
in which participants were asked to continue their nor-
mal diet except to avoid probiotic products (e.g., food 
supplements, yogurt, kefir), the participants consumed 
cheese containing a high dose (100 g) of L. plantarum 
Tensia daily for 3 wk.
Study Population
The participants were randomly chosen from free-
living healthy adults aged 18 to 65 yr. The healthy 
elderly (>65 yr of age) were selected from the registry 
of family doctors and orthopedists of Tartu University 
Clinics (Tartu, Estonia) before orthopedic surgery. The 
demographic and baseline characteristics of partici-
pants are described in Table 3.
The overall inclusion criteria were a desire to par-
ticipate, a suitable age, no known health problems, no 
health conditions that required medication, and no pre-
vious (at least 2 mo) antimicrobial treatment. Subjects 
following special dietary routines; having an unstable 
cardiopulmonary system; with a history of diabetes and 
malignancy, food allergy, acute infection, chronic renal 
or hepatic failure, or gut surgery; with the presence of 
an acute illness 4 wk before the study; having used any 
medication during the last 2 mo; or with a history of al-
cohol abuse, pregnancy, or breastfeeding were excluded 
from participation. For exclusion of participants with 
undiagnosed diabetes, glucose and glycohemoglobin 
were detected in blood sera.
Participants in the trials habitually consumed a 
Western diet. Diets were typically rich in potatoes, 
vegetables, meat, and eggs, but also characterized by a 
high content of fiber (rye bread and oat, wheat, or rice 
porridge) and high-fat dairy products, vegetable seed 
oils, margarine, and nonalcoholic beverages (Adler-
creutz, 1990; Štšepetova et al., 2011).
Questionnaire
In all trials, a self-reported questionnaire was admin-
istered, which contained questions about participants’ 
welfare and any adverse gastrointestinal symptoms (ab-
dominal pain, flatulence, bloating, stool frequency, and 
Figure 1. Design of the double-blind placebo-controlled human 
intervention studies with healthy volunteers (study 1) and the elderly 
(study 2). BL 1 = baseline 1, at recruitment; PRO = after the pro-
biotic treatment; BL 2 = baseline 2, after washout; PL = after the 
control treatment. 
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stool consistency). Questionnaires were completed once 
a week during the trial (Svedlund et al., 1988)
Clinical Investigations
The subjects were clinically investigated, and plasma 
samples were collected after an overnight fast and after 
abstinence from any medications, tobacco, alcohol, tea, 
or coffee. Each participant was evaluated for anthropo-
metrical indices. Body mass index (BMI) was calcu-
lated as the BW (kg) divided by the height squared 
(m2). Overweight was classified as a BMI ≥25.0 and 
normal weight was classified as a BMI <25.0 accord-
ing to the World Health Organization Global Database 
on Body Mass Index (http://apps.who.int/bmi/index.
jsp?introPage=intro_3.html). In TE 5, the hip and 
waist circumference (cm) was measured and the waist-
to-hip ratio was calculated.
In the DBPC trials (TE 1 and ELD), fasting blood 
samples were collected at recruitment, after administra-
tion of the cheese containing L. plantarum Tensia, after 
a washout period, after administration of the control 
cheese, and at the end of the trial. In the open-label tri-
als (TE 5), blood samples were collected at recruitment 
and after the intervention.
Hematological indices (hemoglobin, erythrocytes, 
leukocytes, lymphocytes), inflammatory indices (white 
blood cell count and hs-CRP), metabolic markers [plas-
ma glucose, glycohemoglobin, and lipids, namely, total 
cholesterol, low-density lipoprotein (LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol, and tri-
glycerides], and functionality markers [liver and kidney 
functions: aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), albumin, serum creatinine, 
and immunoglobulin (IgE, IgA, IgM, IgG) levels] were 
determined by standard laboratory methods using 
certified assays in the local clinical laboratory (United 
Laboratories of Tartu University Clinics). Intervals for 
routine laboratory tests proposed by the Nordic Ref-
erence Interval Project (http://www.furst.no/norip/) 
were used as a reference.
Microbiological Analyses of Feces
Quantitative analysis of fecal cultivable lactobacilli 
was performed using conventional serial dilution and 
cultivation methods on MRS media. Samples of feces 
were serially diluted (10−2 to 10−9) in PBS (pH 7.2) in 
an anaerobic glove box (Concept 400, Biotrace Interna-
tional PLC, Bridgend, UK) with a gas mixture consist-
ing of 5% CO2, 5% H2, and 90% N2, and then cultivated 
on freshly prepared MRS agar media (Oxoid). The bac-
teria were quantified by serial dilutions. The microbial 
counts were expressed as log colony-forming units per 
gram of feces. The detection limit of microorganisms 
was 3.0 log cfu/g. Lactobacilli were identified according 
to their biochemical profile by API CHL 50 medium 
(bioMérieux SA, Marcy L’Étoile, France).
Survival of the L. plantarum Tensia strain in the hu-
man gastrointestinal tract was confirmed by randomly 
amplified polymorphic DNA-PCR in TE 1 as follows. 
Genomic DNA of putative Tensia fecal isolates was 
Table 3. Demographic and baseline characteristics of participants (mean ± SD) 
Variable
DBPC1 intervention study Open-label intervention study
Study 1 Study 2 Study 3
Study acronym TE 1 ELD TE 5
ISRCTN2 ISRCTN38739209 ISRCTN45791894 ISRCTN42449576
Study population Adults Elderly Adults
No. of enrolled participants 13 21 29
No. of participants completing the study 12 18 26
No. of dropouts 1 3 3
Sex (male/female) 5/8 1/17 8/18
Age (yr) 29.1 ± 7.7 69.8 ± 5.5 37.2 ± 10.7
BMI3 (kg/m2) 24.1 ± 3.6 27.3 ± 4.2 25.7 ± 4.6
Total cholesterol (mmol/L) 4.6 ± 0.9 5.8 ± 0.8 5.6 ± 1.5
HDL cholesterol4 (mmol/L) 1.7 ± 0.5 1.7 ± 0.3 1.7 ± 0.5
LDL cholesterol5 (mmol/L) 2.7 ± 0.8 3.9 ± 0.8 3.6 ± 1.5
Triglycerides (mmol/L) 1.0 ± 0.6 1.1 ± 0.6 1.2 ± 0.9
HbA1c6 5.6 ± 0.4 5.7 ± 0.2 5.6 ± 0.2
1DBPC = double-blind placebo-controlled.
2ISRCTN = International Standard Randomized Controlled Trial Number.
3BMI = body mass index.
4HDL = high-density lipoprotein.
5LDL = low-density lipoprotein.
6HbA1c = glycohemoglobin.
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extracted from 24-h-old cultures and cultivated micro-
aerobically on MRS agar with a QIAamp DNA Mini 
Kit 50 (Qiagen GmbH) according to the manufacturer’s 
instructions.
Randomly amplified polymorphic DNA-PCR typing 
was done with primer M13 (GAGGGTGGCGGTTCT; 
DNA Technology A/S, Risskov, Denmark). A 50-
μL volume of the reaction mixture consisted of 10× 
PCR buffer (Fermentas), 5 mM MgCl2 (Fermentas), 
200 μM deoxynucleoside triphosphate mixture [2c-de-
oxyadenosine triphosphate (dATP), deoxyguanosine 
triphosphate (dGTP), 2c-deoxythymidine triphosphate 
(dTTP), and 2c-deoxycytidine 5c-triphosphate (dCTP); 
Fermentas], 2.0 μmol/L of each primer, 1.25 U of Taq 
DNA Polymerase (Fermentas), and 100 ng of extracted 
DNA. The PCR mixture was subjected to thermal cy-
cling (Cycler 200r, Eppendorf AG) with 40 cycles of 
denaturation and polymerase activation at 95°C for 5 
min, annealing at 42°C for 2 s, and extension at 72°C 
for 10 min, with a final extension at 72°C for 10 min. 
The PCR products were separated by electrophoresis 
in a horizontal 2% agarose gel containing 0.1 μL/mL 
of ethidium bromide in a Tris-acetic acid-EDTA buffer 
(40 mM Tris, 20 mM boric acid, 1 mM EDTA, pH 
8.3; Bio-Rad Laboratories, Hercules, CA) at a constant 
voltage of 120 V. A 1-kb ladder (GeneRuler; Fermen-
tas) was used as the base pair size marker. The banding 
patterns of the isolates were visualized with UV light 
and compared with those of the L. plantarum Tensia.
Statistical Analysis
The sample size was calculated for crossover studies 
based on a predicted change in cholesterol of 0.1 U in 
the treatment period. Assuming a standard deviation 
of 0.09 U, a sample size of 8 subjects provided suf-
ficient power (80%) to detect a significance level of P < 
0.05 in a paired Student’s t-test calculation. Statistical 
analysis was performed with R software version 2.9.0 
(A Language and Environment, R Project for Statisti-
cal Computing; http://www.r-project.org). Clinical and 
biochemical data were expressed as means ± standard 
deviations. Intestinal lactobacilli counts were expressed 
as log colony-forming units per gram of feces. Baseline 
and intervention data were compared by paired t-test 
or Wilcoxon rank-sum test, according to distribution 
of data.
All data were given as means and standard devia-
tions. Differences were considered statistically signifi-
cant if the value was P < 0.05. The χ2-test was used to 
determine the between-group differences in categorical 
variables (gastrointestinal symptoms). Study power was 
calculated with the program PS: Power and Sample Size 
Calculation (version 3.0; http://biostat.mc.vanderbilt.
edu/PowerSampleSize).
RESULTS
Hemolytic Activity
Lactobacillus plantarum Tensia did not cause the lysis 
of erythrocytes of human and sheep blood in either of 
the environments, whereas complete lysis (β-hemolysis) 
was caused by the strains of Strep. pyogenes and Staph. 
aureus that were used as positive controls.
Antibacterial Susceptibility
The L. plantarum Tensia strain was susceptible to all 
the tested antibiotics. The MIC values corresponded 
to epidemiological cutoff (ECOFF) values for differ-
entiation of wild-type lactobacilli isolates and cultures 
intended for probiotic or nutritional use (Klare et al., 
2005): kanamycin 32 μg/mL (ECOFF 64 μg/mL), 
ampicillin 0.25 μg/mL (ECOFF 2 μg/mL), gentami-
cin 1.5 μg/mL (ECOFF 8 μg/mL), streptomycin 16 
μg/mL (ECOFF 64 μg/mL), erythromycin 0.19 μg/
mL (ECOFF 32.5 μg/mL), clindamycin 0.032 μg/mL 
(ECOFF 0.5 μg/mL), tetracycline 8 μg/mL (ECOFF 
32 μg/mL), chloramphenicol 2 μg/mL (ECOFF 8 μg/
mL), and quinupristin/dalfopristin 1 μg/mL (ECOFF 
1 μg/mL).
Class I Integron and Tetracycline-Resistance Genes
Lactobacillus plantarum Tensia did not possess the 
tetracycline-resistance-determining genes tet(L), tet(S), 
or tet(O), although the tet(K) and tet(M) genes were 
found. The strain did not contain the integron Int1 
gene.
Production of BA
In Decarboxylation Medium. After 4 d at 37°C, 
L. plantarum Tensia produced traces of cadaverine in 
vitro from lysine (0.3 μg/mL) and produced putres-
cine from ornithine (0.5 μg/mL). The strain did not 
decarboxylate arginine or glutamine. Histamine was 
not produced from histidine. The gram-positive control 
strain L. plantarum DSM 21379 produced putrescine 
from ornithine (1.9 μg/mL). The control strain E. coli 
ATCC 700336 was able to produce significant amounts 
of cadaverine from lysine (240 μg/mL), putrescine 
from arginine and ornithine (18.4 and 1,599.3 μg/mL, 
respectively), and histamine from histidine (105.1 μg/
mL).
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In Milk. After incubating the Tensia strain in milk 
at 37°C, tyramine was detected at a concentration of 
6.9 μg/mL on d 12. This concentration decreased to 1.5 
μg/mL by d 40. No other BA were detected.
In Cheese. The formation of most BA, including 
cadaverine and histamine, in cheese during ripening 
and storage was not established. Only tyramine and 
putrescine were found in 3 batches of cheese contain-
ing Tensia in detectable amounts (0.69, 2.65, and 5.49 
mg/kg of tyramine and 1.32, 7.46, and 7.29 mg/kg of 
putrescine, respectively) at the end of ripening (wk 4). 
The corresponding figures for tyramine and putrescine 
in control cheese (regular Edam-type cheese) were 2.31, 
5.64, and 0.1 mg/kg of tyramine and 1.82, 1.84, and 0.1 
mg/kg of putrescine, respectively.
In Vivo Animal Trial
The average consumption rate of cheese per mouse 
was approximately 4.4 g/d. Oral administration of L. 
plantarum Tensia with cheese did not influence the ac-
tivity or general health status of the treated mice over 
30 d. The mean BW of the mice in the test group was 
25.6 ± 1.5 g at the beginning and 32.9 ± 1.6 g at the 
end of the trial. Respective values for the controls were 
26.9 ± 1.3 g and 32.8 ± 1.7 g. Average daily BW gain 
for both groups (test group and control group) was 1.5 
g. The BW gained at the end of the trial was 6.1 and 
6.2 g, respectively. Thus, all mice showed an increase 
in BW.
No statistically significant increase was found in 
the total count of lactobacilli from the small intestine 
(range/median: 3.0–7.1/5.9 log cfu/g in the control 
group vs. 0–5.7/4.7 log cfu/g in the test group) and 
from the large intestine when compared with the con-
trol group (4.4–7.3/6.6 log cfu/g in the control group 
vs. 0–7.0/6.7 log cfu/g in the test group).
No translocation of the administered strain or other 
microbes into the blood or organs was detected. The 
heart blood, liver, kidney, and lung samples obtained at 
autopsy were sterile in all mice. No pathological shifts 
and no micro abscesses, granulomas, or inflammation 
were found by morphological and histological evalua-
tion of the spleen, liver, ileum, and colon of mice.
In Vivo Human Trial Clinical Investigations
Questionnaires. In adults (TE 1), no complaints 
were reported regarding abdominal pain or bloating 
throughout the 3-wk treatment period [verum (i.e., 
cheese containing L. plantarum Tensia) vs. control (i.e., 
regular) cheese; P = 1.0], and no complaints were re-
ported regarding flatulence in wk 1 and 3 (verum vs. 
control; P = 1.0). However, in wk 2 of the treatment, 
25% of participants reported flatulence in the verum 
period (verum vs. control; P = 0.22). No significant 
changes in stool frequency or consistency were reported.
In adults with a high dose of probiotic cheese (TE 5), 
8% of participants reported abdominal pain throughout 
the 3-wk treatment period; flatulence and bloating were 
reported by 27% of participants throughout the 3-wk 
treatment period. Approximately 62% of participants 
reported hard stools in wk 2 and 3 of the trial in com-
parison with the run-in period (P = 0.023).
In the study with the elderly (ELD), participants 
reported no significant abdominal pain (23%, verum 
vs. control; P = 1.0), flatulence (50%, verum vs. con-
trol; P = 1.0), or bloating (20%, verum vs. control; P 
= 1.0) throughout the trial in both treatment periods 
(probiotic and control). No significant changes in stool 
frequency or consistency were reported.
Abdominal Obesity and BMI. No significant 
changes were detected in BMI (TE 1: baseline 24.1 ± 
3.6 to 24.2 ± 3.6 kg/m2, P = 0.584; ELD: 27.6 ± 4.1 
vs. 27.5 ± 4.2 kg/m2, P = 0.723; TE 5: 25.7 ± 4.6 vs. 
25.7 ± 4.7 kg/m2, P = 0.319) following the 3-wk con-
sumption of probiotic cheese. The additional markers 
of abdominal obesity, namely, waist circumference (cm) 
and waist-to-hip ratio, in adults consuming the highest 
dose of 100 g/d for 3 wk (TE 5) also did not increase 
(baseline 0.808 ± 0.075 vs. end of trial 0.806 ± 0.073; 
P = 0.351)
Blood Serum Glucose and Lipids. In TE 1, no 
changes in the level of blood serum glucose were detect-
ed (probiotic period: 4.5 ± 0.7 vs. 4.6 ± 0.5 mmol/L, P 
= 0.922; control period: 4.6 ± 0.6 vs. 4.7 ± 0.5 mmol/L, 
P = 0.289; Table 4).
In the elderly (ELD), a significant increase of 0.3 U 
was found in blood serum glucose content (from 5.1 ± 
0.5 to 5.4 ± 0.5 mmol/L, P = 0.036) after probiotic 
cheese consumption (Table 4). However, the increase 
did not exceed the normal reference values by the Nor-
dic Reference Interval Project (M/F >18 yr: 3.3 to 5.5 
mmol/L). On the other hand, in adult volunteers (TE 
5), a statistically significant reduction (P = 0.0005) 
in blood serum glucose (from 5.3 ± 0.4 to 5.0 ± 0.5 
mmol/L) was registered after 3 wk of probiotic cheese 
consumption at the high dose (Table 4). No correla-
tions between the changes in glucose contents with age, 
sex, or gastrointestinal health status and BMI were 
established. Blood serum lipid (total, HDL, and LDL 
cholesterol) levels remained unchanged in all groups 
consuming probiotic cheese in comparison with the 
recruitment values (Table 4).
Inflammation Markers. After the 3-wk probiotic 
treatment, the values of systemic inflammation markers 
(hs-CRP and white blood cell count) stayed within the 
normal range in both adults and the elderly (Table 5). 
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Table 4. Effect of 3 wk of consumption of 50 g [studies 1 (TE 1) and 2 (ELD)] or 100 g [study 3 (TE 5)] of probiotic cheese containing Lactobacillus plantarum Tensia on blood 
serum glucose and lipid values of adult volunteers (TE 1, TE 5) and the elderly (ELD; mean ± SD)1 
Variable2
Test period
P-value, 
PRO vs. BL1
Control period
P-value,  
BL2 vs. PL Reference interval by NORIP3BL1 PRO BL2 PL
TE 1 (n = 12)
 Total cholesterol (mmol/L) 4.6 ± 0.9 4.6 ± 1.1 0.828 4.2 ± 0.6 4.5 ± 0.9 0.102 30 to ≤ 50 yr: 3.3 to 6.9.mmol/L
 HDL cholesterol (mmol/L) 1.7 ± 0.5 1.7 ± 0.3 0.628 1.6 ± 0.4 1.7 ± 0.4 0.433 ≥18 yr: 1.2 mmol/L
 LDL cholesterol (mmol/L) 2.7 ± 0.8 2.8 ± 1.1 0.296 2.6 ± 0.7 2.6 ± 0.7 0.827 30 to ≤50 yr: 1.4 to 4.7.mmol/L
 TG (mmol/L) 1.0 ± 0.6 1.0 ± 0.5 0.978 0.9 ± 0.4 1.2 ± 0.7 0.140 ≥18 yr: 0.45 to 2.6.mmol/L
 Glycose (mmol/L) 4.5 ± 0.7 4.6 ± 0.5 0.922 4.6 ± 0.6 4.7 ± 0.5 0.289 ≥18 yr: 3.3 to 5.5 mmol/L
ELD (n = 18)
 Total cholesterol (mmol/L) 5.7 ± 0.8 5.6 ± 0.8 0.343 5.9 ± 0.9 5.7 ± 0.8 0.198 >50 yr: 3.9 to 7.8 mmol/L
 HDL cholesterol (mmol/L) 1.7 ± 0.4 1.6 ± 0.4 0.411 1.7 ± 0.4 1.7 ± 0.5 0.514 ≥18 yr: 1.2 mmol/L
 LDL cholesterol (mmol/L) 3.9 ± 0.8 3.8 ± 0.7 0.557 4.1 ± 0.9 3.8 ± 0.7 0.052 ≥50 yr: 2.0 to 5.3 mmol/L
 TG (mmol/L) 1.1 ± 0.6 1.1 ± 0.6 0.380 1.2 ± 0.5 1.1 ± 0.5 0.394 ≥18 yr: 0.45 to 2.6.mmol/L
 Glycose (mmol/L) 5.1 ± 0.5 5.4 ± 0.5 0.036 5.3 ± 0.5 5.4 ± 0.4 0.144 ≥18 yr: 3.3 to 5.5 mmol/L
TE 5 (n = 26)
 Total cholesterol (mmol/L) 5.6 ± 1.5 5.5 ± 1.4 0.151 ND4 ND — 30 to ≤50 yr: 3.3 to 6.9 mmol/L
 HDL cholesterol (mmol/L) 1.7 ± 0.5 1.7 ± 0.4 0.187 ND ND — ≥18 yr: 1.2 mmol/L
 LDL cholesterol (mmol/L) 3.6 ± 1.5 3.7 ± 1.4 0.761 ND ND — 30 to ≤50 yr: 1.4 to 4.7 mmol/L
 TG (mmol/L) 1.2 ± 0.9 1.0 ± 0.5 0.183 ND ND — ≥18 yr: 0.45 to 2.6 mmol/L
 Glycose (mmol/L) 5.3 ± 0.4 5.0 ± 0.5 0.0005 ND ND — ≥18 yr: 3.3 to 5.5 mmol/L
1BL1 = baseline 1, at recruitment; PRO = after the probiotic treatment; BL 2 = baseline 2, after washout; PL = after the control treatment.
2HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides.
3Reference intervals for both sexes; NORIP = Nordic Reference Interval Project.
4ND = not determined.
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In both age groups, no changes in the contents of IgA, 
IgM, and IgG antibodies were detected. Most impor-
tant, no change was detected in the values of the es-
sential allergy marker IgE or in kidney and liver mark-
ers (serum creatinine, albumin, ALT, or AST; Table 
6). Even consumption of the higher dose of probiotic 
cheese had no negative effect on the aforementioned 
indices (Table 6).
Intestinal Lactobacilli. The total counts of in-
testinal cultivable lactobacilli increased significantly 
during the period of probiotic cheese consumption for 
both adults (TE 1; 5.5 ± 1.1 vs. 6.7 ± 1.0 log cfu/g, 
P = 0.047) and the elderly (ELD; mean value 5.2 ± 
2.7 vs. 6.9 ± 1.4 log cfu/g, P = 0.017; Figure 2). No 
significant changes were seen with the consumption of 
control cheese.
The cheese strain administered, L. plantarum Tensia, 
was detectable in the fecal samples of 10 of 12 adult 
participants (TE 1) after probiotic consumption, at 
counts of 6.0 ± 1.5 log cfu (range: 3.2 to 8.6; median: 
6.3), and after a 2-wk washout period, was detectable 
in the fecal samples of 2 subjects, at counts of 4.2 ± 0.2 
log cfu (range: 4.0 to 4.3; median: 4.2).
DISCUSSION
We found that the addition of a particular probiotic 
strain to cheese did not affect the gut functionality 
indices or metabolism of the host. In this study, we ap-
plied the L. plantarum strain Tensia, originating from a 
healthy child (Mikelsaar et al., 2002). The human origin 
of the strain is a prerequisite for its harmless status and 
suitability for oral application. Generally, L. plantarum 
is a common indigenous component of human intestinal 
microbiota (Mikelsaar et al., 2002, 2010; de Vries et al., 
2006). Moreover, L. plantarum as a species is consid-
ered by the European Food Safety Authority suitable 
for the qualified presumption of safety (QPS) approach 
(EFSA, 2007).
In characterizing a probiotic strain, the absence of 
antibiotic-resistance genes is of utmost importance. 
Mobile genetic elements containing genes determining 
resistance to erythromycin, tetracycline, and vancomy-
cin have been found among lactobacilli (Tannock, et al., 
1994; Gevers et al., 2003a,b; Mathur and Singh, 2005). 
The prevalence of tet genes in Lactobacillus isolates has 
been reported earlier (Klare et al., 2005; Gevers et al., 
2003a,b). In L. plantarum Tensia, the tet(K) and tet(M) 
genes, although present, were not expressed. Gevers et 
al. (2003a,b) showed, in Lactobacillus isolates with the 
chromosomal tet gene, significantly lower tetracycline 
MIC values than in the case of plasmid-encoded tet-
racycline resistance (32 to 48 μg/mL and >192 g/mL, 
respectively). Thus, because we did not find phenotypic Ta
b
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tetracycline resistance in L. plantarum Tensia, it can 
be predicted as nontransferable. However, more studies 
are needed to verify this prediction.
Probiotics, as viable microbes with the ability to sur-
vive and be metabolically active in the gastrointestinal 
tract, have led to several areas of concern (Hibberd and 
Davidson, 2008). First is the potential of the probiotic 
to translocate and cause invasive infection (Salminen et 
al., 2004; Cannon et al., 2005). The absence of trans-
location and the absence of histologically detected pa-
thologies in the NIH mouse experimental model proved 
the safety of the strain L. plantarum Tensia. Moreover, 
interaction with the gastrointestinal mucosa and the 
effect on the composition of the intestinal microbiota 
may also have serious consequences. Feeding the Lac-
tobacillus strain of human origin for a period of 30 d 
did not result in an increase in the total number of 
lactobacilli in the mouse gut. This could be due to the 
human origin of the strain but also to strain specificity. 
It has been shown that feeding a human strain of Lac-
tobacillus to mice does not always result in an increase 
in total counts of lactobacilli (Truusalu et al., 2004).
In our human study, the content of total lactobacilli 
increased in feces, and the presence of the ingested pro-
biotic strain was confirmed after the consumption of 
cheese. Mutual interactions take place between a pro-
biotic strain and the indigenous microbiota of the host 
in the small intestine. The consumption of probiotics 
may influence the metabolism and population of the 
indigenous microbiota.
It has been shown that ingestion of a certain pro-
biotic may increase the total number of indigenous 
lactobacilli (Sepp et al., 1993; Goossens et al., 2003; 
Wind et al., 2010). The increase in Bifidobacterium and 
Lactobacillus spp. levels in the gut are correlated with 
numerous health markers. Microbiota changes attribut-
able to probiotic intake include increased numbers of 
related phylotypes, a decrease in pathogens and their 
toxins, stabilization of the bacterial communities when 
perturbed (e.g., with antibiotics), and the promotion 
of a more rapid recovery from a perturbation (Floch et 
al., 2011).
A relatively high amount (10.3 log cfu/serving for 3 
wk) of the probiotic strain in the cheese was consumed 
by adult volunteers. For the elderly, who are a more 
vulnerable population group, the daily dose was low-
ered: 8.17 log cfu daily for 3 wk. No adverse side effects 
(flatulence, bloating, abdominal pain, stool frequency) 
were detected with 50 g of cheese consumption in adults. 
The consumption of cheese in a double dose caused 
Table 6. Effect of 3 wk of consumption of 50 g [studies 1(TE 1) and 2 (ELD)] or 100 g [study 3 (TE 5)] of 
probiotic cheese containing Lactobacillus plantarum Tensia on metabolic markers of adult volunteers (TE 1, 
TE 5) and the elderly (ELD; mean ± SD)1 
Variable2
Probiotic cheese Control cheese
P-valueBL1 PRO BL2 PL
TE 1
 AST (U/L) 20.2 ± 5.4  ND3 ND 18.3 ± 5.4 0.129
 ALT (U/L) 17.7 ± 5.6 ND ND 16.2 ± 4.3 4 0.247
 Albumin (g/L) 45.9 ± 2.6 ND ND 45.2 ± 1.8 0.283
 Serum creatinine (μmol/L) 73.8 ± 12.0 ND ND 70.9 ± 10.3 0.122
 IgE (kU/L) 31.7 ± 21.1 ND ND 28.9 ± 19.9 0.174
 IgA (g/L) 1.7 ± 0.7 ND ND 1.7 ± 0.6 0.29
 IgM (g/L) 1.4 ± 0.7 ND ND 1.4 ± 0.7 0.966
 IgG (g/L) 11.2 ± 1.6 ND ND 11.1 ± 1.5 0.671
ELD
 AST (U/L) 21.4 ± 4.2 ND ND 22.1 ± 4.4 0.334
 ALT (U/L) 20.2 ± 8.7 ND ND 22.8 ± 9.4 0.050
 Albumin (g/L) 42.0 ± 2.3 ND ND 41.7 ± 2.8 0.548
 Serum creatinine (μmol/L) 65.4 ± 9.7 ND ND 64.6 ± 10.9 0.779
 IgE (kU/L) 53.9 ± 85.8 ND ND 42.8 ± 63.6 0.064
 IgA (g/L) 2.4 ± 1.3 ND ND 2.4 ± 1.2 0.664
 IgM (g/L) 1.2 ± 0.6 ND ND 1.2 ± 0.6 0.205
 IgG (g/L) 10.3 ± 1.5 ND ND 10.8 ± 1.5 0.098
TE 5
 AST (U/L) 21.9 ± 6.3 22.8 ± 6.0 ND  0.319
 ALT (U/L) 21.2 ± 9.4 22.0 ± 11.3 ND  0.508
 Albumin (g/L) 44.5 ± 2.0 43.9 ± 2.0 ND  0.390
 Serum creatinine (μmol/L) 69.8 ± 14.6 67.5 ± 12.7 ND  0.128
1BL1 = baseline 1, at recruitment; PRO = after the probiotic treatment; BL 2 = baseline 2, after washout; PL 
= after the control treatment.
2AST = aspartate aminotransferase; ALT = alanine aminotransferase.
3ND = not determined.
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single cases abdominal pain, flatulence, bloating, or 
their combination. Because the daily dose of probiotic 
was similar in both studies with adult volunteers, such 
indigestion could have been caused by the consump-
tion of cheese in excess, not by the probiotic strain. In 
the elderly, one-fourth of the participants complained 
about abdominal pain or bloating, and one-half of 
the participants reported flatulence throughout the 
entire trial. Because abdominal pain (12.5%), bloating 
(41.6%), and flatulence (63.3%) were also reported dur-
ing the run-in period, these kinds of complaints seem to 
be symptoms of an age-related decline in physiological 
functions. Cheese is rich in saturated fats and proteins 
and lacks fiber; therefore, excessive consumption of 
cheese could result in constipation. We found that only 
the consumption of 100 g/d for 3 wk caused hard stools 
during the second week of the trial.
Lactobacilli could exhibit certain disadvantageous 
metabolic activities with regard to consumer safety, 
particularly if BA accumulate in the fermented products 
(Bernardeau et al., 2008). Biogenic amines have been 
implicated in several outbreaks of food poisoning and 
are the initiators of hypertensive crises, hypertension or 
hypotension, and dietary-induced migraines in certain 
patients. Nonstarter lactic acid bacteria (including lac-
tobacilli) are associated with cheese-related outbreaks 
of histamine poisoning (Novella-Rodríguez et al., 2002). 
Aged cheeses, such as Cheddar, Emmenthaler, and Stil-
ton, typically contain moderate to high concentrations 
of BA, including tyramine. The amount of clinically 
significant tyramine per serving is considered >6 mg 
(McCabe-Sellers et al., 2006). The cheese used in the 
present study was Edam-type cheese because this vari-
ety is the most common in Estonia and has a ripening 
period that is relatively short in comparison with other 
cheese varieties (e.g., Cheddar, Parmesan). Therefore, 
the possibility of the appearance of very high quanti-
ties of BA into this cheese variety is unlikely. However, 
the incorporation of relatively high viable counts of a 
human strain of L. plantarum into a protein-rich food 
matrix can trigger unwanted metabolic activity of the 
strain. Furthermore, L. plantarum has been identified 
as a producer of BA in Edam-type cheese (Bunková et 
al., 2010). Therefore, the possible appearance of BA in 
cheese containing L. plantarum Tensia was assessed in 
the present work. We demonstrated that the strain L. 
plantarum Tensia does not produce potentially harmful 
BA, such as histamine or cadaverine. The amount of 
tyramine produced in the cheese during ripening and 
15 wk of storage was below the clinically significant 
content.
Damage to liver function is caused by liver cell dam-
age, resulting in the leakage of enzymes into the blood 
circulation, indicating injury by various substances, 
including food. On the other hand, Higashikawa et 
al. (2010) reported a remarkable improvement in liver 
function in healthy adults, according to the serum 
enzymes (including AST and ALT), with intake of 
cultured yogurt containing a L. plantarum strain, and 
Ranganathan et al. (2010) reported a lowering of the 
creatinine level in patients with chronic kidney disease 
when given a probiotic supplement containing L. aci-
dophilus and Bifidobacterium longum. In our trials with 
Figure 2. Changes in counts of cultivable fecal lactobacilli during 
the studies: a) study 1 (TE 1); b) study 2 (ELD). BL 1 = baseline 1, 
at recruitment; PRO = after the probiotic treatment; BL 2 = baseline 
2, after washout; PL = after the control treatment. The transverse line 
within the box indicates the median value; the bars extending from 
each box represent the 25th and 75th percentiles; and the open circles 
represent outliers.
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adult and elderly volunteers, no changes were registered 
in the values of kidney and liver function markers (se-
rum creatinine, albumin, ALT, and AST) because of 
probiotic cheese consumption.
No adverse effects on inflammation markers in the 
blood (WBC count and IgG, IgM, and IgE levels) were 
detected. In addition, the hs-CRP values were stable in 
the long-lasting trials. This is a very important finding 
because C-reactive protein is a marker of inflammation 
strongly correlated with CVD (Danesh et al., 1998; 
Moss and Freed, 2003).
Milk fat is considered one of the major sources of 
dietary cholesterol. The consumption of full-fat variet-
ies of cheese allegedly increases the blood cholesterol 
level. In our study, the effect of fat on host plasma 
lipids by participants consuming, for 3 plus 3 wk, the 
semihard Edam-type cheese (fat content 26%) with and 
without the probiotic additive was considered negli-
gible. No negative effect on levels of total cholesterol or 
cholesterol fractions (HDL cholesterol, LDL cholesterol, 
triglycerides) was observed. Some reports indicate that 
unlike other full-fat dairy products, such as whole milk 
or butter, consumption of cheese confers lesser plasma 
lipid levels, increasing the effect at comparable intakes 
of total fat and saturated fat (Biong et al., 2004; Thol-
strup et al., 2004; Nestel et al., 2005). Some authors 
suggest that probiotic cultures could beneficially influ-
ence the absorption of dietary fat and cholesterol in the 
small intestine (Agerholm-Larsen et al., 2000; Raff et 
al., 2008).
Abdominal obesity has been associated with an in-
creased risk of type 2 diabetes, dyslipidemia, hyper-
tension, and especially CVD (de Koning et al., 2007). 
In contrast, the Hoorn study, with an elderly Dutch 
population, showed a significant inverse association 
between consumption of high-fat dairy products and 
BMI, waist circumference, and blood triglyceride in-
dices and a positive correlation with HDL cholesterol 
(Snijder et al., 2007). In the present study, no BW gain 
was detected in the elderly consuming 50 g of cheese 
even though they were figured as being a less physically 
active population subgroup, or in adults consuming 50 
or 100 g of cheese daily for 3 wk.
The statistically significant (P = 0.0005) decrease in 
blood serum glucose in adults because of a high dose 
of cheese consumption is probably because cheese has 
a low glycemic index but is otherwise a nutrient-dense 
food that helps postpone the feeling of hunger.
CONCLUSIONS
The present work demonstrates the safety of consum-
ing a regular semihard Edam-type cheese (fat content 
of 26%) with and without the probiotic additive L. 
plantarum Tensia at a daily dose of 50 g and in excess 
(100 g), and with a daily dose of probiotic of 10 log cfu 
for 3 wk, with no harmful effect on gut health, BMI, 
inflammatory markers, or serum lipidograms.
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